 OUTLINE: This is a randomized randomized part of study completed as of 62005, open-label, multicenter study. Patients are stratified according to participating center, value for serum lactic dehydrogenase no greater than upper limit of normal ULN vs greater than ULN, bulky disease present no vs yes, stage I or II vs III or IV, general ECOG status of patient 0 or 1 vs 2, and age 61 to 70 vs 71-80. Patients are randomized to 1 of 4 treatment arms. Patients with CD20-negative lymphoma are randomized to arms I or II only. 